Current status of ramucirumab in gastroesophageal adenocarcinoma.

about

Current status of ramucirumab in gastroesophageal adenocarcinoma.

Item

http://www.wikidata.org/entity/Q38691733

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Current status of ramucirumab in gastroesophageal adenocarcinoma.

@en

type

Item

label

Current status of ramucirumab in gastroesophageal adenocarcinoma.

@en

prefLabel

Current status of ramucirumab in gastroesophageal adenocarcinoma.

@en

P1476

Current status of ramucirumab in gastroesophageal adenocarcinoma

@en

P2093

Elena Elimova

http://www.w3.org/2001/XMLSchema#string

Quan Lin

http://www.w3.org/2001/XMLSchema#string

Shumei Song

http://www.w3.org/2001/XMLSchema#string

P2860

The structural basis for the function of two anti-VEGF receptor 2 antibodies

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

P304

1585-1592

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0556

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jaffer Ajani

P577

2017-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28436242

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma